QuantHealth Raises $45M to Simulate Clinical Trials with AI

QuantHealth, an Israeli startup pitching drug companies on the idea that they should run trials in a simulator before running them on people, raised $45 million in Series B funding led by Qumra Capital, Fierce Healthcare reported. The round pulled in Sanofi Ventures, Pitango HealthTech, Bertelsmann Healthcare Investments, Artofin, GC Ventures, NewHealth, Shoni Top, and Esplanade Ventures, and takes total funding to about $70 million since the company was founded in 2020 by Orr Inbar and Arnon Horev.

The pitch aims straight at pharma's most painful number. Roughly 90% of clinical-stage drugs fail, three quarters of them on efficacy or safety, which is the point at which a sponsor has already committed years of work and significant capital. QuantHealth's platform tries to move that decision earlier, running an AI simulation of a proposed trial against synthetic patient cohorts to see how it would play out before real enrollment starts. The company says it has now simulated more than 600 trials across 30 disease indications, claims up to 90% predictive accuracy on those runs, and counts 12 of the world's top 20 pharmaceutical companies as customers.

The claim worth interrogating is that accuracy figure. Up to 90% is a company self-report, not a regulator-validated endpoint, and none of the coverage this week names a specific past trial where a QuantHealth simulation would have flagged a failure the sponsor missed. It also matters that Sanofi is both an investor via Sanofi Ventures and the sort of pharma customer QuantHealth is selling into, an alignment that is common in this corner of biotech but worth keeping in view when you read the traction numbers.

For AI Weekly this lands in a busier than usual stretch of healthcare AI and funding coverage, and it is the more interesting flavour of clinical AI, aimed at the design phase of an expensive process rather than at chatbot triage. Stanford's Evo 2 designing 16 working phages earlier this month worked the same design-phase problem from the molecule side. If simulation-first design starts working its way into how big sponsors defend Phase II decisions to their boards, the vendors already embedded in top-20 pharma workflows get a very useful moat.